Skip to main content

Table 3 Cardiotoxicity events by clinical risk score

From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

  Clinical Risk Score
Low (0–3) Moderate (4–5) High (≥ 6)
Patients (n) 90 (70) 25 (19) 12 (9)
Cardiotoxicity [n (%)] 6 (4) 5 (4) 2 (1)
Permanent reduced EF [n (%)] 5 (4) 2 (1) 1 (0.1)